<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814955</url>
  </required_header>
  <id_info>
    <org_study_id>A15-D20-VOL.25</org_study_id>
    <nct_id>NCT02814955</nct_id>
  </id_info>
  <brief_title>Electrophysiological Effects of NACOS and AVK on Pulmonary Veins and Left Atrium in Paroxysmal AF Catheter Ablation</brief_title>
  <acronym>NACO-VP</acronym>
  <official_title>Study of Electrophysiological Effects of NACOS and AVK on the Pulmonary Veins and the Left Atrium of Patients Referred for Paroxysmal AF Catheter Ablation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common cardiac arrhythmias with a constantly growing&#xD;
      prevalence AF. The purpose of paroxysmal AF processing is to control outbreaks from these&#xD;
      pulmonary veins, medicated way (antiarrhythmic) or interventional. Ablation (radiofrequency&#xD;
      or cryotherapy) has become in this context recognized and effective treatment of AF. In&#xD;
      addition, antithrombotic treatments in this context is a major treatments for the prevention&#xD;
      of stroke (stroke). They are most often associated with antiarrhythmic treatment to prevent&#xD;
      recurrence of AF or to slow it during a relapse.&#xD;
&#xD;
      Recent experimental studies have highlighted the direct electrophysiological properties of&#xD;
      dabigatran and rivaroxaban in the pulmonary veins and the left atrium. Dabigatran&#xD;
      demonstrated in this study that it induced a prolongation of potential action in the&#xD;
      pulmonary veins and the left atrium and it decreased the incidence of FA-induced by&#xD;
      stimulation. Conversely, rivaroxaban induces shortening of the action potential in the left&#xD;
      atrium (untested properties in the pulmonary veins). To our knowledge, apixaban and warfarin&#xD;
      have not been studied in this context.&#xD;
&#xD;
      It is therefore possible that some of the new oral anticoagulants (NACOS) or some AVK&#xD;
      (fluindione and warfarin), have direct electrophysiological effects in the pulmonary veins&#xD;
      and on the left atrium and could influence AF recurrences (with effect &quot; antiarrhythmic-like&#xD;
      &quot;or rather a pro-arrhythmic effect) after ablation.A retrospective analysis conducted at the&#xD;
      University Hospital of Caen on very low numbers suggest that patients on dabigatran would&#xD;
      have less pulmonary veins connected in early ablation procedure that patients on warfarin or&#xD;
      rivaroxaban. Despite the limitations inherent in this analysis (very low numbers,&#xD;
      retrospective analysis, unique setting and having studied his own limits), these results are&#xD;
      consistent with the fundamental studies, and thus encourage us to pursue our hypothesis to&#xD;
      obtain more statistical power and reliability in our measurements and results.&#xD;
&#xD;
      We therefore propose the study of the electrophysiological effects of NACOS (apixaban,&#xD;
      dabigatran, rivaroxaban) and warfarin (warfarin and fluindione) on the pulmonary veins and&#xD;
      the left atrium of patients referred for ablation of paroxysmal AF (radiofrequency or&#xD;
      cryotherapy ) the CHU of Caen and Tours and clinic Saint Martin Caen.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Reccurence of atrial fibrillation</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of active pulmonary veins</measure>
    <time_frame>1 day</time_frame>
    <description>Measure at the ostia with the lasso</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spontaneous cycle length in active pulmonary veins</measure>
    <time_frame>1 day</time_frame>
    <description>Measure at the ostia with the lasso</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of connected pulmonary veins</measure>
    <time_frame>1 day</time_frame>
    <description>Measure at the ostia with the lasso</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of refractory period for each pulmonary veins and left atria</measure>
    <time_frame>1 day</time_frame>
    <description>Measure at the ostia with the lasso for each VP, and with coronary sinus for the LA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of re-connected pulmonary veins with ATP</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>referred for paroxysmal atrial fibrillation with fluindione</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>referred for paroxysmal atrial fibrillation with previscan</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>referred for paroxysmal atrial fibrillation with apixaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>referred for paroxysmal atrial fibrillation with rivaroxaban</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>referred for paroxysmal atrial fibrillation with dabigatran</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      cordarone&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population corresponds to all patients referred for paroxysmal atrial&#xD;
        fibrillation radiofrequency ablation , clinically stable, at Caen University Hospital,&#xD;
        Tours and Saint-Martin clinic.&#xD;
&#xD;
        These patients have a strict, rigorous and systematic follow after these ablation at 1, 3&#xD;
        and 6 months with routine ECG.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All hospitalized patients for ablation of paroxysmal AF&#xD;
&#xD;
          -  On healthy heart&#xD;
&#xD;
          -  Sinus rhythm during the procedure&#xD;
&#xD;
          -  Patient&gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient &lt;18 years&#xD;
&#xD;
          -  Severe Mitral valve disease,&#xD;
&#xD;
          -  underlying heart disease&#xD;
&#xD;
          -  Patients refusing to participate to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Joachim Alexandre, MD</last_name>
    <email>alexandre-j@chu-caen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Alexandre Joachim</name>
      <address>
        <city>Caen</city>
        <state>Basse Normandie</state>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Alexandre, MD</last_name>
      <email>alexandre-j@chu-caen.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>June 23, 2016</last_update_submitted>
  <last_update_submitted_qc>June 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>pulmonary veins</keyword>
  <keyword>oral anticoagulant</keyword>
  <keyword>electrophysiology</keyword>
  <keyword>anticoagulant drugs</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

